AstraZeneca scores 13 points higher than Pfizer on SINK's sustainability index.
AstraZeneca is more sustainable according to SINK's open sustainability index, scoring 52/100 vs Pfizer's 39/100 — a difference of 13 points.
Pfizer scores 39/100 on the SINK sustainability index (Below expectations). Pfizer discloses robust climate data with GHG Protocol alignment and SBTi validation, but progress is dire: only 15% of its 46% emissions reduction target achieved by 2024, renewable energy stuck at 14% despite RE100 membership, and hazardous waste flat since 2022. Critically, Pfizer's climate messaging is undermined by active membership in trade associations (US Chamber, NAM) that lobby against climate policy.
AstraZeneca scores 52/100 on the SINK sustainability index (Making progress). AstraZeneca has cut operational emissions 77.5% since 2015 and locked in science-based net-zero targets, but absolute supply chain emissions are rising 18.6% from baseline. Operations excel; supply chain and delivery risk on Scope 3 are the dominant weaknesses. Trade association memberships undermine climate advocacy clarity.
Both companies are rated on the same 10-question SINK rubric: Scope 1/2/3 carbon footprint, energy source, nature and biodiversity, resource use, water, emissions trajectory, science-based targets, transparency, and controversies. Scores are 0–100, based on public data, and fully reproducible.
See the full leaderboard — 500+ companies ranked.
View full leaderboard →